DEEP LEARNING IN DRUG DISCOVERY AND DIAGNOSTICS MARKET ANALYSIS

Market News

Key Developments

Research and development activities related to deep learning in drug discovery and diagnostics is expected to boost the market growth. For instance, on September 2, 2019, Insilico Medicine Hong Kong Ltd. reported development of a deep generative model, generative tensorial reinforcement learning (GENTRL), for de novo small-molecule design. GENTRL was used to discover potent inhibitors of discoidin domain receptor 1 (DDR1), a kinase target implicated in fibrosis and other diseases, in 21 days.

Key players in the market are focused on adopting collaboration and partnership strategies to enter in the emerging market. For instance, in February 2019, Juvenescence AI, Ltd., a drug development company focused on combating ageing and age-related diseases, collaborated with NetraMark Corp., a company that uses machine learning algorithms to redesign failing drugs, to form a joint venture, NetraPharma.

Major market players are also focused on raising funding to support their product development. For instance, in August 2019, Verisim Life, Inc., a U.S.-based biotechnology startup that uses AI-powered biosimulations to replace animal drug testing, announced it has raised $5.2 million in a round of funding led by Serra Ventures and OCA Ventures.